Editas Medicine, Inc. (Nasdaq: EDIT) has announced the appointment of Linea Aspesi as its Executive Vice President and Chief People Officer. Ms. Aspesi will leverage her expertise to drive Editas’ human resources department and lead the Company’s people strategy in pursuit of its mission and goals. With her on board, Editas is well-positioned to continue its journey towards becoming a premier clinical-stage genome editing company.
Linea Bayles brings impressive expertise in talent strategy and will be an invaluable asset to Editas Medicine in its journey to becoming a commercial-stage organization. With her guidance, the Leadership Team will be able to leverage the talent of the team to transform the lives of people living with serious diseases. We are thrilled to have Linea’s expertise to help drive our success and are eager to work with her to reach our ambitious goals.
At Editas Medicine, we recognize that our people are the key to our success. That’s why we are thrilled to launch our new strategy to reengage, inspire, and empower our talented team to be the driving force behind our company. We are committed to making a difference in the lives of patients across the globe and look forward to partnering with our Leadership Team and employees to make it happen. Linea Aspesi, our Executive Vice President and Chief People Officer, is excited to lead the charge and make this vision a reality.
With over two and a half decades of experience, Ms. Aspesi has been a driving force in the life sciences sector for the past 15 years. She has a talent for aligning her plans with a company’s vision, mission and values, as well as partnering with senior leaders to define and implement strategies to promote cultural transformation. Ms. Aspesi brings this invaluable experience to Editas.
Ms. Aspesi has joined Editas from Forma Therapeutics, where her expertise in Human Resources led to the successful completion of the US $1B acquisition by Novo Nordisk. Prior to Forma, she served as Saniona’s first Chief Human Resources Officer and held positions of increasing responsibility at Sanofi and Genzyme, most recently as Head of Human Resources for their Industrial Affairs organization in North America. Ms. Aspesi has a wealth of experience in leading people elements of successful mergers and acquisitions.
Ms. Aspesi is a proud graduate of the University of Massachusetts, Amherst, having earned her Bachelor of Arts in Education. She is a testament to the power of hard work and dedication, having achieved this remarkable accomplishment through her unwavering commitment and drive.
About Editas Medicine
Editas Medicine is on a mission to revolutionize healthcare by using the power of CRISPR/Cas9 and CRISPR/Cas12a genome editing systems. As a clinical-stage genome editing company, Editas Medicine seeks to develop transformative, durable, precision genomic medicines for a wide range of diseases, and is the exclusive licensee of Broad Institute and Harvard University’s Cas9 patent estates and Broad Institute’s Cas12a patent estate for human medicines. By harnessing the potential of genome editing, Editas Medicine is committed to bringing hope and treatments to people living with serious diseases across the globe.